Introduction: In the era of biomarker-driven systemic therapy for advanced NSCLC, the role of routine repeated biopsies for decision making outside EGFR-mutant disease remains unproven. We report our center's experience of safety and adequacy for molecular retesting of tumor material obtained from image-guided lung rebiopsies in NSCLC.
Introduction
Lung cancer is the most common cause of cancerrelated mortality in men and women worldwide, 1, 2 with more than 80% classified as NSCLC. Identification of driver somatic aberrations in advanced NSCLC has led to rational implementation of genotype-directed therapy, with international guidelines recommending molecular testing 3, 4 because EGFR and ALK kinase inhibitors have demonstrated markedly superior efficacy over chemotherapy in those harboring activating EGFR mutations and ALK receptor tyrosine kinase gene (ALK) rearrangements, respectively, and they are licensed for firstline therapy, alongside ROS1 kinase inhibitors. [5] [6] [7] [8] [9] [10] However, multiple mechanisms of acquired resistance to molecular-directed therapy have been identified, including emergence of additional somatic mutations with reduced affinity for the drug (for instance, the EGFR T790M gatekeeper 11 ) but also other less common mechanisms such as histological nonconcordance [12] [13] [14] or bypass track activation (e.g., through gene amplification). 15 Therapeutic strategies to overcome mechanisms of acquired resistance are being developed, and in some cases licensed. For example, the EGFR mutation-specific kinase inhibitor osimertinib is active against both classical activating EGFR mutations (e.g., L858R or exon 19 deletion) and the resistance mutation T790M, resulting in U.S. Food and Drug Administration and European Medicines Agency licenses for NSCLC progressing during or after a first-line EGFR tyrosine kinase inhibitor (TKI) (afatinib, erlotinib, or gefitinib) and with evidence of T790M mutation. 16, 17 Other potentially targetable somatic aberrations have been identified in up to 70% of patients with the adenocarcinoma subtype of NSCLC 18 and in more than 50% of squamous NSCLC, 19 and a variety of global efforts are under way to identify and validate the efficacy of genotype-directed therapy in relapsed NSCLC through multiarm multiagent designed trials, such as the National Cancer Institute MATCH trial (NCT02465060) and the U.K. National Lung MATRIX Trial (NCT02664935). Although circulating tumor DNA (ctDNA) genotyping is an effective and validated technology for some alleles (e.g., EGFR T790M), contingent on clinical setting, the low specificity of some genotyping technologies coupled with the low ctDNA shedding rate for M1a NSCLC may limit clinical interpretation.
Therefore, repeated biopsies for purposes of molecular characterization may be indicated for the optimal management of patients with relapsed advanced NSCLC and are recommended, especially in tumors with oncogene addiction, to identify resistance-associated genotypes and guide therapy choice. 3, 20 Image-guided percutaneous transthoracic core needle biopsies are a standard diagnostic tool used to obtain tumor tissue at the point of diagnosis or relapse. Safety and tissue diagnostic yields of biopsies at first diagnosis of lung cancer are well established. [21] [22] [23] However, the data remain limited on the adequacy of tumor material obtained by repeat image-guided percutaneous biopsies to molecularly characterize tumors for clinical decision making. Here, we report our center's experience of safety and adequacy for molecular testing of tumor material obtained from image-guided transthoracic rebiopsies in patients with NSCLC.
Methods
This is a retrospective analysis of patients undergoing image-guided lung rebiopsies at a single cancer center between 2011 and 2014. Rebiopsy was defined as biopsy after cancer progression after anticancer therapy (any line) or repeated biopsy in cases in which initial histological or molecular analysis was inadequate or incomplete for clinical decision making. This study was approved by the local audit committee.
Patients
Patients were identified through a search of electronic patient records for those with a diagnosis of NSCLC who were undergoing image-guided lung biopsies between November 2011 and April 2014. Patients with other primary thoracic malignancies (e.g., SCLC, mesothelioma, thymic malignancies, and carcinoid tumors) were excluded.
Individual case notes were hand-searched for predefined data items, including fields on demography (age, sex, smoking history, pulmonary comorbidities, and history of other malignancies), lung cancer (diagnosis, disease stage, number of previous lines of systemic anticancer treatment, and somatic mutational status at biopsy time), rebiopsy data (biopsy indication, image guidance mode, number of passes, needle gauge, and number of cores obtained), postprocedure complications (pneumothorax, hemoptysis, and hospitalization), and rebiopsy tissue sample (presence/ absence of malignancy, histological subtype, molecular analysis performed, mutations identified, molecular success, and molecular failure reasons). A validated data capture spreadsheet was created and populated by two independent investigators (N. T. and S. B.), who reviewed case notes and identified and entered data. Disagreements were reviewed and consensus sought with arbitration by a third reviewer (S. P.).
Objectives
The primary objective was to determine the pathological success rate, defined as the proportion of rebiopsy cases confirmed to contain malignant cells (as documented in the pathology reports).
Secondary and exploratory objectives included determination of the following: technical success rate; concordance of prebiopsy and postbiopsy histological subtype; adequacy of rebiopsy material for molecular analysis; number and nature of new mutations identified; and incidence of complications.
Definitions
Technical success was defined as successful insertion of biopsy needle into the target lesion, with cells or lung tissue present in the specimen, as documented in the pathology reports. Histological concordance was determined by comparison of the original histological diagnoses, as documented in case notes, with histological diagnoses based on rebiopsy specimens, which were reviewed and classified by a dedicated lung pathologist using the 2015 WHO classification. Diagnostic biopsies were re-reviewed by a dedicated thoracic pathologist where possible. Molecular analysis of rebiopsy material was performed as clinically indicated for individual cases. Adequacy of rebiopsy material for molecular analysis was defined as a minimum of 30% viable tumor cells in a sample, as assessed by a dedicated thoracic pathologist per routine practice. Reasons for inadequacy as reported by the pathologist were identified by case note review and grouped into consistent themes. Posttest molecular success rate was defined as the proportion of successfully informative individual gene analyses out of the total number of genes analyzed.
Statistical Analysis
Differences in intergene failure rates were tested by using the chi-square test for comparing multiple proportions with a significance level of a equal to 0.05, with Bonferroni correction for multiple pairwise comparisons. The relationship between number of cores (<3 vs. 3 cores) and molecular adequacy was tested by using Fisher's exact test.
Results

Patients
A total of 103 patients were identified from searching case notes for patients with a diagnosis of thoracic malignancy who underwent image-guided percutaneous transthoracic procedures between November 2011 and April 2014. Seven patients had pleural drain insertion or pleural fluid aspiration and were excluded from analysis. Of the 103 patients, 16 underwent an initial diagnostic biopsy for suspected lung cancer (14 to obtain a histological diagnosis and two for completion of staging at diagnosis) and were excluded from further analysis, as this was an initial biopsy as opposed to a rebiopsy. In addition, 14 patients with a diagnosis of other thoracic malignancy, including 10 mesotheliomas, two SCLCs, and two thymic malignancies, were excluded from further analysis.
In all, 66 patients with NSCLC rebiopsy were included in the final analysis. Patient characteristics are summarized in Table 1 .
Procedures
The mode of image guidance was computed tomography (CT) in 60 of 66 cases (91%) and ultrasonography in six cases (9%). Four patients had a CT-guided chest wall biopsy. All procedures were performed by an experienced interventional radiologist using dedicated CT-guided biopsy software (i-sequence and i-spiral) on a Somatom Definition Edge CT scanner (Siemens, Erlangen, Germany). Rapid on-site evaluation was not used for any of the procedures. Although all rebiopsies were considered for molecular analysis, the primary indications for rebiopsy varied. Most patients underwent rebiopsy primarily for molecular testing (41 of 66 [62.1%]), including 11 patients for first-time molecular analysis, 13 patients for repeat analysis on account of previous failure, 11 for expanded molecular profiling, and six for EGFR T790M mutation detection. In 12 patients, the documented primary indication for repeat biopsy was histological confirmation of disease relapse; in four patients, the primary indication was to exclude clinical suspicion of high-grade neuroendocrine transformation; and in two patients, it was disease restaging. Seven of 66 patients had a rebiopsy in the context of a research protocol.
Technical success was achieved in all 66 patients (a rate of 100%). The mean target lesion size was 40.7 mm (95% confidence interval: 35.9-45.5), with a mean distance to pleura of 15 mm (95% confidence interval: 11.35-18.55). A range of needle gauge sizes was used, from 14G to 18G, with most of the procedures performed using an 18G needle (45 of 52 cases [86%] in which needle gauge size was documented). The median number of cores obtained was 3 (range 1-6), in one case the number was reported as multiple, and in 3 cases it was not documented. Target lesion locations were evenly distributed between all lobes of the lung (53% in the upper lobes and 45% in the lower lobes), with one lesion located in the right middle lobe.
Pathological Findings
Pathological success was achieved in 54 of all 66 patients (81.8%). In eight patients no malignant cells were found in the sample. Presence or absence of malignant cells was not evaluable in four cases in which rebiopsy was performed as part of a research protocol. These four cases were not evaluated for histopathology and were therefore excluded from further analyses. Therefore, the pathological success rate for evaluable cases was 54 of 62 (87.1%).
Histological concordance was evaluable in 52 cases (in two of the 54 cases containing malignant cells histological subtype was not reported on rebiopsy tissue). Concordance of prerebiopsy and postrebiopsy histological subtype was observed in 40 of 52 cases (76.9%). Discordance was observed in 12 cases (23.1%), as detailed in Table 2 . In one case, the histopathological features of the rebiopsy sample were consistent with thymoma (in a patient with known synchronous diagnoses of NSCLC adenocarcinoma and thymoma).
Molecular Analysis
A total of 52 cases were adequate for further molecular analysis as subjectively determined by the lung pathologist, resulting in a pretest molecular adequacy of 78.8% of all rebiopsy cases. Two cases containing malignant cells (pathologically successful) were inadequate for molecular analysis owing to poor sample quality.
Molecular analysis was performed in 51 of 66 patients, resulting in a total of 209 genes analyzed. In one patient whose rebiopsy sample showed NSCLC with rhabdoid differentiation, the tissue was subjectively adequate for molecular analysis but molecular testing was not requested, as it was not clinically indicated.
The genes analyzed on at least one occasion were EGFR, ALK, KRAS, NRAS, BRAF, dicoidin domain receptor tyrosine kinase 2 gene (DDR2), ROS1, and rearranged during transfection proto-oncogene gene (RET). Individual polymerase chain reaction-based gene assays were performed; they included the following: cobas 480 a Total of 52 cases were evaluable for histological concordance. Of the 14 cases that were not evaluable, eight had no malignant cells in the sample (pathological fail), four were sent to a research laboratory, and two did not have the histological subtype reported. NOS, not otherwise specified; TTF-1, thyroid transcription factor 1.
(Roche, Basel, Switzerland) for EGFR and KRAS mutations; capillary electrophoresis single-strand conformation analysis for EGFR, BRAF exon 15 mutation, and NRAS mutations; and direct sequencing for BRAF exon 11 and DDR2, as next-generation sequencing was not routinely implemented during this period. Fluorescence in situ hybridization was used to detect ALK and ROS1 rearrangements. • EGFR (n = 48)
• ALK (n = 39)
• KRAS (n = 31)
• BRAF exon 15 (n = 33)
• BRAF exon 11 (n = 21)
Technical failure (n = 0) Molecular failure n = 27 (22.9%)
• EGFR (n = 2)
• ALK (n = 1)
• KRAS (n = 10)
• BRAF exon 15 (n = 7)
• BRAF exon 11 (n = 6) • EGFR (n = 9)
• ALK (n = 2)
• KRAS (n = 11)
• NRAS (n = 1)
Inadequate for molecular analysis (n = 2)
• Poor sample quality (n = 2)
Total number of genes analyzed (n = 209) Figure 1 . CONSORT diagram. RMS, Royal Marsden Hospital; ALK, ALK receptor tyrosine kinase gene; DDR2, dicoidin domain receptor tyrosine kinase 2 gene; RET, rearranged during transfection proto-oncogene gene.
A total of 182 of 209 genes were analyzed successfully (evaluable), with a posttest molecular success rate of 87.1% (Fig. 1) .
There was significant intergene variation in molecular failure rates (p ¼ 0.005). For instance, EGFR analysis was performed in 50 patients and ALK analysis was performed in 40, with molecular failure rates of 4% and 2.5%, respectively, whereas KRAS was analyzed 41 times, with a failure rate of 24.4% (p ¼ 0.04 and p ¼ 0.04, respectively). Rates of molecular success and failure by gene are shown in Table 3 . The observed intergene variation in failure rates is likely due to the sequential nature of the individual gene tests performed, with less material available for each subsequent analysis.
The reason for failure of molecular analysis, where recorded, was always poor sample quality. We explored a possible relationship between number of cores obtained and molecular adequacy and found no significant difference in molecular failure rates between cases in which fewer than three cores were obtained and those with three or more cores (p ¼ 0.185). There did not appear to be any clear links between incidence of molecular test failure and patient characteristics or technical aspects of rebiopsy.
In all, 24 genetic aberrations were identified, including 20 new (previously unknown) potentially targetable mutations. They included activating mutations in EGFR in two patients in whom molecular testing had previously failed (one EGFR exon 19 deletion and one S768I point mutation); two EGFR T790M acquired resistance mutations; and one EGFR primary resistance mutation (exon 20 deletion). ALK rearrangements were identified in two patients. Eleven patients were found to have a KRAS mutation, one patient had a NRAS Q61L mutation, and one had a DDR2 mutation.
Safety
The rate of all complications was 25.7% (in 17 of 66 patients). Presence of pneumothorax was assessed in all patients by postprocedure plain chest radiograph or limited postprocedure chest CT and confirmed in 12 of 66 cases (18.2%). However, only two of 12 cases required intervention with chest drain insertion (3.0%). The median age of patients experiencing a pneumothorax was similar to that of the overall study population: 63 years (range 37-76) versus 67 years . The rate of previous or current smoking was slightly higher in the pneumothorax group than in the overall population (83.3% vs. 71.2%), but no one in the pneumothorax group had a history of significant pulmonary comorbidities (compared with a rate of 13% in the overall group).
Hemoptysis was reported in five of 66 cases (7.6%) and not recorded in two patients. All cases were categorized as mild hemoptysis (<30 mL over 24 hours) not requiring further intervention. Two patients (3.0%) required prolonged postprocedure (>48 hours) hospitalization for management of pneumothorax necessitating chest drain insertion. Three patients required a prolonged admission for unrelated reasons.
Postrebiopsy Clinical Outcomes
We extracted data on postrebiopsy clinical treatment pathways to explore the ways in which rebiopsy affected clinical decision making. These data are summarized in Table 4 . In 42 of 66 patients (63.6%), rebiopsy had a direct impact on the choice of subsequent treatment, including in 13 (19.7%) who began receiving licensed targeted therapies for newly identified somatic mutations (including seven [54%] in a clinical trial setting) or histological subtype-specific chemotherapy. Four patients (6%) were too unwell for further systemic therapy after rebiopsy.
Discussion
We have reported a retrospective study of the adequacy of image-guided transthoracic rebiopsies in 66 patients in terms of safety, technical success rates, and adequacy for pathological and molecular analysis. With a 100% technological success rate, 87.1% pathological adequacy, and 78.8% molecular adequacy as subjectively assessed by a lung pathologist, we have shown that image-guided lung rebiopsies are feasible and can yield tissue adequate for analysis of multiple biomarkers in the setting of standard clinical practice. We report rates of pneumothorax (18%), chest drain insertion (3%), and mild hemoptysis (8%) that are similar to those previously reported in large series of percutaneous transthoracic biopsies in the primary diagnostic setting, [24] [25] [26] [27] and we therefore conclude that rebiopsy is not associated with any increased risk compared with primary biopsies.
We observed a relatively high rate of histological discordance (23%) between rebiopsy material and prior diagnostic biopsies. In cases in which histological discrepancy was observed, the initial diagnostic biopsies were re-reviewed where available to explore possible causes for the differences. In two cases in which squamous cell carcinoma at initial biopsy was reclassified as adenocarcinoma on rebiopsy and where diagnostic biopsy material was available for review, rebiopsy tumor material showed some features of overlap between adenocarcinoma and squamous cell carcinoma. The discordance between biopsy samples may therefore reflect sampling of different components of the same tumor with features of both adenocarcinoma and squamous cell carcinoma. Another possible explanation for the observed differences may be sampling bias, with patients whose initial samples were inadequate for optimal histological assessment and diagnosis selected for rebiopsy, leading to higher rates of histological discordance in our cohort (e.g., three instances of NSCLC not otherwise specified were reclassified as squamous cell carcinoma).
Overall, 182 of 209 individual gene tests (87.1%) were performed successfully in 51 patients. Molecular success rates varied significantly between individual gene assays. EGFR testing was completed successfully in 48 of 50 cases (96%), which is in line with the rates reported in several previous studies of adequacy of rebiopsy tissue for EGFR testing. 14, [28] [29] [30] [31] Two prospective studies of rebiopsies in 121 patients 30 and 162 patients 14 with acquired resistance to EGFR TKIs reported rates of 86% and 95.6%, respectively. Another recent prospective study enrolled 24 patients with EGFR mutation who began receiving afatinib therapy with a view to rebiopsy for EGFR T790M analysis at progression. Of 23 patients in whom progressive disease developed, only 14 completed a rebiopsy, with 11 samples (78.6%) sufficient for molecular analysis. 31 Most studies of rebiopsies have focused on mechanisms of acquired resistance to EGFR TKIs (in particular, detection of T790M mutation), and few studies have evaluated adequacy for multiple biomarker testing on rebiopsy tissue outside of this context. [32] [33] [34] Tam et al. have reported a retrospective analysis of adequacy of percutaneous transthoracic core needle biopsies for the evaluation of multiple molecular biomarkers within the context of the genotype-directed BATTLE trial. 33 A total of 170 biopsies were performed in 151 patients NSCLC who were screened for the trial. Specimens from 82.9% of patients were found to have adequate tumor tissue for analysis of 11 different biomarkers within EGFR, KRAS, BRAF, vascular endothelial growth factor receptor (VEGFR), retinoid X receptor gene (RXR), and cyclin D genes. The rates of pneumothorax and chest tube insertion were 15.3% and 9.4%, respectively. In our study, the rates of pretest (87.1%) and posttest (78.8%) molecular adequacy were similar to those reported in the BATTLE trial despite our relatively unselected patient cohort in the setting of standard clinical practice.
The main limitation of this study is that it is a retrospective observational study based on the clinical experience of a single oncology center. As a tertiary referral center and an institution with a well-established infrastructure and experience in this area, our experience may not be representative of the patient profile and resources available in other community-based centers. Second, the discrepancy between subjective pathologistassessed pretest molecular adequacy and posttest molecular success rate has been difficult to explore in the absence of complete data on the reasons for test failure. Third, incomplete data on the technical aspects of each procedure precluded analysis of the potential relationship between incidence of molecular analysis failure and the way in which procedures were performed, which would help define optimal conditions to obtain adequate tissue samples. Finally, instead of single-gene tests performed in parallel or sequentially, many centers have now moved to implementing next-generation sequencing-based molecular genotyping [35] [36] [37] [38] ; therefore, the individual molecular success rate at individual genes may not reflect changes in gene testing methodologies.
Choice of optimal treatment and development of treatment strategies in NSCLC are predicated by tumor histological and molecular characterization. Repeated molecular profiling is likely to be required at multiple time points during the treatment pathway, as is already the case for detection of the EGFR T790M mutation, 20 given the interpatient and intrapatient molecular heterogeneity identified from sequencing studies 39 and the evolutionary pressures of molecular selection from targeted therapy in oncogene-addicted NSCLCs. Nevertheless, in a real-world setting, our data have identified the clinical utility and limitations of rebiopsies in advanced NSCLCs, demonstrating a clinically important utility in decision making and for molecular characterization. Improvements in the histological yield and molecular adequacy of rebiopsies may be achieved by implementation of standardized protocols and algorithms in radiology departments and laboratories to ensure optimal handling of samples for molecular analyses as highlighted in the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. 4 Use of rapid on-site evaluation of specimens at time of the procedure has been shown to improve diagnostic yield, decrease the need for repeat procedures, and facilitate collection of sufficient material for molecular testing, 40 although resource considerations are likely to affect widespread use of this technique.
Validation of ctDNA for genotyping is facilitating a less invasive approach for detection of EGFR T790M at the point of progression, 41 but tissue-based verification remains an important strategy to identify patients suitable for EGFR T790M inhibitors, especially because of the low sensitivity of some ctDNA testing methods. It is also important to verify other resistance mechanisms, such as histological nonconcordance, and to stratify patients for other systemic therapies within clinical trials. In our study rebiopsies produced clinically relevant information, helping to guide the choice of treatment in nearly two-thirds of patients through identification of new actionable driver and resistance mutations, change in histological classification, and confirmation or exclusion of recurrent disease.
Our study provides valuable data on the role and utility of rebiopsy for molecular analysis of multiple molecular markers in a heterogeneous group of patients with NSCLC in the setting of standard clinical practice. We have validated the pathological and molecular adequacy rates of rebiopsies and demonstrated clinical utility in routine decision making.
